Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.21)
# 2,684
Out of 4,862 analysts
46
Total ratings
43.48%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $15.48 | +35.66% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $600 → $300 | $2.92 | +10,173.97% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $8.33 | -27.97% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $62.36 | -42.27% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $12.53 | +299.04% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $41.31 | +287.32% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $8.42 | +375.06% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $39.12 | +168.40% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $54.07 | -50.06% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $128.16 | -21.97% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.32 | +2,055.17% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $4.28 | +6,208.41% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.18 | +13,459.32% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $15.48
Upside: +35.66%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $600 → $300
Current: $2.92
Upside: +10,173.97%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $8.33
Upside: -27.97%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $62.36
Upside: -42.27%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $12.53
Upside: +299.04%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $41.31
Upside: +287.32%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $8.42
Upside: +375.06%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $39.12
Upside: +168.40%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $54.07
Upside: -50.06%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $128.16
Upside: -21.97%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.32
Upside: +2,055.17%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $4.28
Upside: +6,208.41%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.18
Upside: +13,459.32%